期刊
ENDOCRINOLOGIA Y NUTRICION
卷 63, 期 5, 页码 239-249出版社
ELSEVIER ESPANA SLU
DOI: 10.1016/j.endonu.2016.01.001
关键词
Statins; HMG-CoA reductase inhibitors; Ditag-related side effect; Statin intolerance; Myotoxicity; Myopathy
Statin therapy has a very important role in decreasing cardiovascular risk, and treatment non-compliance may therefore be a concern in high cardiovascular risk patients. Myotoxicity is a frequent side effect of statin therapy and one of the main causes of statin discontinuation, which limits effective treatment of patients at risk of or with cardiovascular disease. Because of the high proportion of patients on statin treatment and the frequency of statinrelated myotoxicity, this is a subject of concern in clinical practice. However, statin-related myotoxicity is probably underestimated because there is not a gold standard definition, and its diagnosis is challenging. Moreover, information about pathophysiology and optimal therapeutic options is scarce. Therefore, this paper reviews the knowledge about the definition, pathophysiology and predisposing conditions, diagnosis and management of statin-related myotoxicity, and provides a practical scheme for its management in clinical practice. (C) 2016 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据